Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

August 31, 2003

Primary Completion Date

February 28, 2005

Conditions
General Anxiety Disorder
Interventions
DRUG

GABITRIL (tiagabine hydrochloride; CEP-6671)

Trial Locations (28)

10021

Fieve Clinical Services, Inc., New York

10023

Medical and Behavioral, New York

10024

Medical Research Network, New York

11235

Social Psychiatry Research Ins, Brooklyn

19104

University of Pennsylvania, Philadelphia

22041

Comprehensive Neuroscience Of, Falls Church

27609

Richard Weisler, MD and Assoc, Raleigh

29407

South East Health Consultants, Charleston

30080

Carman Research, Smyrna

32216

Clinical Neuroscience Solution, Jacksonville

33407

Clinical Neuroscience Solution, West Palm Beach

48336

Summit Research Network Farmin, Farmington Hills

62025

Cunningham Clinical Research, Edwardsville

77401

Claghorn-Lesem Research, Bellaire

80212

Radiant Research Denver, Denver

84107

Radiant Research Salt Lake, Salt Lake City

85210

Pivotal Research Center, Mesa

90210

Southwestern Research, Beverly Hills

91324

Pharmacology Research Institut, Northridge

92103

Radiant Research San Diego, San Diego

92108

Affiliated Research Institute, San Diego

92660

Pharmacology Research Institut, Newport Beach

92868

Pacific Clinical Research Medi, Orange

97210

Summit Research Network Inc., Portland

98104

Summit Seattle Boren, Seattle

06030

University of Connecticut, Farmington

02114

Massachusetts General Hospital, Boston

08021

CNS Research Institute, Clementon

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cephalon

INDUSTRY

NCT00233675 - Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder | Biotech Hunter | Biotech Hunter